ArticleKidney medicine2025
Anti-GBM Disease Following Ovarian Mesonephric-Like Adenocarcinoma: A Unique Insight Into Paraneoplastic Autoimmunity.
Article in Kidney medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesonephric-like adenocarcinoma (MLA) of the ovary is an exceptionally rare malignancy, and antiglomerular basement membrane (anti-GBM) disease has not previously been described in this setting. We report a 63-year-old woman with FIGO (Fédération Internationale de Gynécologie et d'Obstétrique) stage IIIA1(i) ovarian MLA who underwent complete cytoreduction followed by 6 cycles of carboplatin-paclitaxel. Four months after chemotherapy, she developed fatigue, hematuria, and rapidly progressive kidney failure; serology revealed high-titer anti-GBM antibodies. Despite urgent plasma exchange, high-dose corticosteroids, cyclophosphamide, rituximab, and maintenance hemodialysis, renal recovery was minimal. The close temporal sequence raises, but does not establish, a possible link between MLA, its cytotoxic treatment, and the emergence of anti-GBM autoimmunity, perhaps through chemotherapy-mediated alteration or exposure of glomerular antigens. Although causality remains speculative and additional cases are required for confirmation, our observation suggests that autoimmune vasculitides should remain within the differential diagnosis of otherwise unexplained fulminant kidney injury in patients with rare gynecological malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.